[go: up one dir, main page]

UY31522A1 - Nanoparticulas con superficie modificada - Google Patents

Nanoparticulas con superficie modificada

Info

Publication number
UY31522A1
UY31522A1 UY31522A UY31522A UY31522A1 UY 31522 A1 UY31522 A1 UY 31522A1 UY 31522 A UY31522 A UY 31522A UY 31522 A UY31522 A UY 31522A UY 31522 A1 UY31522 A1 UY 31522A1
Authority
UY
Uruguay
Prior art keywords
nanoparticles
modified surface
compositions
kits
drugs
Prior art date
Application number
UY31522A
Other languages
English (en)
Inventor
Sascha General
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31522A1 publication Critical patent/UY31522A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones de nanopartículas con la superficie modificada cargadas de droga, conjuntos de elementos (kits) para uso farmacéutico que contienen a los componentes individuales de dichas composiciones, los usos médicos de las mismas, así como un método para producir dichas composiciones.
UY31522A 2007-12-10 2008-12-10 Nanoparticulas con superficie modificada UY31522A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1255307P 2007-12-10 2007-12-10
EP07076065A EP2070521A1 (en) 2007-12-10 2007-12-10 Surface-modified nanoparticles

Publications (1)

Publication Number Publication Date
UY31522A1 true UY31522A1 (es) 2009-08-03

Family

ID=40383696

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31522A UY31522A1 (es) 2007-12-10 2008-12-10 Nanoparticulas con superficie modificada

Country Status (7)

Country Link
EP (1) EP2070521A1 (es)
AR (1) AR069639A1 (es)
PA (1) PA8807001A1 (es)
PE (1) PE20091271A1 (es)
TW (1) TW200932287A (es)
UY (1) UY31522A1 (es)
WO (1) WO2009074233A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
TWI406842B (zh) * 2010-05-28 2013-09-01 Nat Univ Tsing Hua 表面修飾的奈米粒子及其製造方法
US10307372B2 (en) * 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2567702A1 (en) * 2011-09-12 2013-03-13 Johannes-Gutenberg-Universität Mainz A particulate system comprising lanthanides for use in diminishing cell growth/inducing cell killing
EP2928500B1 (en) * 2012-12-04 2019-03-06 Phosphorex Inc. Microparticles and nanoparticles having negative surface charges
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US262030A (en) 1882-08-01 Wash-stand
US258286A (en) 1882-05-23 Fruit-drier
US252028A (en) 1882-01-10 Alonzo s
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
FR2684103B1 (fr) 1991-11-22 1994-09-02 Centre Nat Rech Scient Nouveaux composes a structure guanidique et composition pharmaceutique les contenant.
DE69529054T2 (de) 1994-02-28 2003-08-21 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
PT1186606E (pt) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19728914A1 (de) 1997-07-07 1999-01-14 Basf Ag Metallisch gefärbte Polyamide
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US7407975B2 (en) 1997-08-09 2008-08-05 Bayer Schering Pharma Ag Epothilone derivatives, method for producing same and their pharmaceutical use
EP1021168A4 (en) * 1997-10-09 2006-08-30 Univ Vanderbilt MICRO AND NANOAPARTICULAR, POLYMERIC ADMINISTRATION SYSTEM
DE19745950A1 (de) 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE19820599A1 (de) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
WO1999067253A2 (en) 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
SE517641C2 (sv) 1998-07-02 2002-07-02 Sca Hygiene Prod Ab Förfarande för att framställa ett materialskikt med barriärflikar samt ett ytskikt med sådana barriärflikar
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
DE19908760A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19908763A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE50014587D1 (de) 1999-02-18 2007-10-04 Bayer Schering Pharma Ag 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
DE19907588A1 (de) 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh C-21 Modifizierte Epothilone
EP1165067A4 (en) 1999-03-29 2002-06-26 Bristol Myers Squibb Co METHOD FOR PREPARING AZYRIDINYLEPOTHIOLONS FROM OXIRANYLEPOTHILONS
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
WO2001027308A2 (en) 1999-10-08 2001-04-19 Novartis Ag 13-alkyl epothilone derivatives
AU2001243372A1 (en) 2000-03-01 2001-09-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
DE10020517A1 (de) 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US20020045609A1 (en) 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
WO2002008440A2 (en) 2000-07-25 2002-01-31 Kosan Biosciences, Inc. Fermentation process for epothilones
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
IL155306A0 (en) 2000-10-13 2003-11-23 Univ Mississippi Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
DE50111753D1 (de) 2000-10-16 2007-02-08 R & D Biopharmaceuticals Epothilon-synthesebausteine i: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie deren verwendung zur herstellung von epothilonen und epothilonderivaten
AU2002338336A1 (en) 2001-04-03 2002-10-21 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
DE60325718D1 (de) 2002-05-06 2009-02-26 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
US20090004277A1 (en) 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen

Also Published As

Publication number Publication date
PE20091271A1 (es) 2009-09-20
WO2009074233A1 (en) 2009-06-18
TW200932287A (en) 2009-08-01
AR069639A1 (es) 2010-02-10
PA8807001A1 (es) 2009-07-23
EP2070521A1 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CR20110579A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
UY33130A (es) Derivados de imidazopiridina como inhibidores de jak
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP088666A (es) Derivados de las benzamidas y heteroarenos
CR9786A (es) Compuestos de bencimidazol-tiofeno
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
DOP2018000082A (es) NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
ECSP077271A (es) Derivados de pirimidina
UY28876A1 (es) Compuestos de morfolina sustituida y composiciones para el tratamiento de trastornos del sistema nervioso central
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
ECSP077259A (es) Derivados de pirimidina
ECSP14013215A (es) Compuestos novedosos
ECSP099620A (es) Derivados de ciclohexano espirociclico
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
UY31922A (es) Compuestos
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171019